Analysis
Two clinical-stage biotechs, Bambusa Therapeutics and Aspen Neuroscience, priced their IPOs within hours of each other late on October 29, 2026, with both beginning to trade on the Nasdaq Global Select Market the next morning -- Bambusa as BBTX, Aspen as ASPE, part of what BioSpace tracks as 2026's biotech IPO class. Pulse covered each pricing separately: this piece looks at what the pairing says about where the biotech IPO market stands.
The two deals, side by side
- Bambusa Therapeutics (BBTX) -- upsized to 10,555,555 shares, priced at $16.00, for $168.9M in gross proceeds; joint book-runners BofA Securities, Evercore ISI, UBS Investment Bank and Cantor.
- Aspen Neuroscience (ASPE) -- 9,375,000 shares, priced at $15.00, for about $140.6M in gross proceeds; joint bookrunners Leerink Partners, Piper Sandler, Stifel, UBS Investment Bank and Oppenheimer & Co.
Both deals priced inside or at the midpoint of their marketed ranges rather than being cut to get done, which IPO-tracking desks generally read as a sign of real investor demand rather than a discount sale.
“Aspen's own numbers illustrate a pattern worth tracking across this biotech IPO class: - Aspen IPO, Oct 30 -- about $140.6M raised.”
What the pairing says about investor appetite
BioSpace, which tracks 2026's biotech IPO class, describes analysts as cautiously optimistic about a rebound in biopharma listings after a prolonged drought -- language that implies selectivity rather than blanket enthusiasm for every clinical-stage name that files. Bambusa and Aspen represent two different paths to the same outcome: Bambusa is a comparatively new filer completing a standard IPO process, while Aspen's listing follows through on an IPO filing plan Pulse covered weeks earlier, after the company had already raised roughly $340 million-plus privately.
Public price versus private price
Aspen's own numbers illustrate a pattern worth tracking across this biotech IPO class:
- Aspen IPO, Oct 30 -- about $140.6M raised.
- Aspen Series C, Nov 2025 (private) -- $115M raised, one of several private rounds ahead of the IPO.
- Aspen total private capital before the IPO -- over $340M, more than the IPO itself raised.
A public raise smaller than everything a company raised privately suggests some biotechs are using IPOs more for liquidity and a public trading currency than for raising their single largest check -- a different motivation than a company using an IPO primarily to fund its next clinical readout.
What to watch next
The test now is how BBTX and ASPE actually trade once the first full session closes: a first-day pop for one but not the other would say more about investor discrimination by pipeline stage than either company's own fundamentals. Watch also whether more biotechs follow with IPOs priced at or above the midpoint of their range in November and December, which would be a stronger signal of a durable reopening than two deals pricing the same week.
The risk in reading too much into one strong week: two same-day debuts is a small sample, and both of these companies are pre-revenue, clinical-stage businesses whose IPO pricing reflects investor appetite for the story, not proof that either therapy will clear the trials ahead of it.